News Servier signs €1bn-plus AI pact with Iktos In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.
News Insilico adds Servier to partnership roster with $888m deal Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.
R&D From complexity to cohesion: AI’s growing role in building s... AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.
News Insilico ends 2025 with $293m Hong Kong IPO One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
News Chai raises $130m for AI drug discovery platform AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
